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Key Points




We conducted a
Delphi-method survey
with lymphoma
experts to deﬁne
modern enrollment
criteria for ﬁrst-line
DLBCL RCTs.
We deﬁned 31
modernized eligibility
criteria to facilitate
enrollment of a
clinically diverse study
population in ﬁrst-line
DLBCL RCTs.

Recent ﬁrst-line randomized controlled trials (RCTs) for patients with diffuse large B-cell
lymphoma (DLBCL) have shown negative results, which may be due in part to onerous
eligibility criteria limiting enrollment of poor-risk patients who require immediate
treatment. We conducted a Delphi-method survey with lymphoma experts in the United
States to deﬁne recommendations for essential and potentially unnecessary enrollment
criteria for modern ﬁrst-line DLBCL RCTs aimed at increasing clinical diversity of
ensuing study groups. We ﬁrst tabulated enrollment criteria from 19 DLBCL RCTs
spanning the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
(R-CHOP) era to identify common eligibility criteria from prior DLBCL RCTs for inclusion
in the Delphi-method survey. We tabulated 451 total eligibility criteria comprising 51
criterion categories across 19 ﬁrst-line DLBCL RCTs in the R-CHOP era. We then surveyed
lymphoma clinical trial experts representing 8 academic medical centers in the United
States regarding essential and unnecessary eligibility criteria for modern DLBCL RCTs.
Seventeen of 29 invited clinical investigators completed the round-1 questionnaire
(response rate, of 58.6%), 15 of 17 round-1 participants (88.2%) completed the round-2
survey, and all round-1 participants reviewed ﬁnalized recommendations for eligibility
criteria for modern ﬁrst-line DLBCL RCTs. We deﬁned consensus recommendations for
31 modernized eligibility criteria including threshold values for 10 quantitative eligibility
criteria aimed at facilitating enrollment of a clinically diverse study population in
ﬁrst-line DLBCL RCTs designed to improve standard-of-care therapy.

Submitted 1 November 2021; accepted 24 January 2022; prepublished online on Blood
Advances First Edition 31 January 2022; ﬁnal version published online 29 April 2022.
DOI 10.1182/bloodadvances.2021006504.
Presented in abstract form at the 61st annual meeting of the American Society of
Hematology, Orlando, FL, 7 to 10 December 201928 and at the 62nd annual
meeting of the American Society of Hematology, virtual conference, 5 to 8 December 2020.29

The full-text version of this article contains a data supplement.
© 2022 by The American Society of Hematology. Licensed under Creative
Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NCND 4.0), permitting only noncommercial, nonderivative use with attribution. All other
rights reserved.

Surveys and anonymized results from all survey rounds are found in supplemental
data. Please contact andrew.harkins@emory.edu for additional original data.
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Introduction

A key observational study showed that shorter diagnosis-to-treatment interval (DTI) is strongly associated with inferior event-free
survival in newly diagnosed DLBCL.12 In the discovery cohort
(n 5 986 patients prospectively enrolled in the University of Iowa
and Mayo Clinic Molecular Epidemiology Resource) and validation
cohort (n 5 1444 patients prospectively enrolled in the Lymphoma
Study Association LNH-2003 clinical trials program), the median
DTIs were 14 days (range, 0-155 days) and 23 days (range, 0-215
days), respectively. In both cohorts, patients with a DTI ,14 days
experienced reduced 24-month event-free survival when compared
with patients with DTI .14 days. In the multivariable logistic regression model involving both cohorts, longer DTI predicted improvement in 24-month event-free survival, independent of clinical factors
in the international prognostic index (IPI), with per-week odds ratios
of 0.83 (95% conﬁdence interval, 0.76-0.91; P , .001) and 0.93
(95% conﬁdence interval, 0.88-0.98; P , .001) in the discovery
and validation cohorts, respectively, in IPI-adjusted models.
This ﬁnding has implications for bias in DLBCL RCTs as patients
who require rapid treatment are less likely to undergo the often
time-consuming steps necessary to determine trial eligibility. Somewhat paradoxically, this results in reduced trial participation by the
very patients who are most in need of improved treatment
approaches: those with inferior outcomes on standard therapy. For
instance, most recent RCTs for patients with DLBCL have
described DTIs much longer than 14 days (eg, the ROBUST trial,
which reported a median DTI of 31 days).11 When study populations are enriched for patients with longer DTI despite the use of
poor-risk IPI eligibility criteria, we should expect improved survival in
the control arms as was seen in US and European patients treated
with R-CHOP,12 which may contribute to negative study results
overall.5-11 Even the ﬁrst-line POLARIX trial that met its primary endpoint had a mean DTI of 26 days.13
Efforts to revise trial enrollment processes and reduce DTIs
among study populations have signiﬁcant potential to limit bias
in modern ﬁrst-line DLBCL RCTs and increase the likelihood of
observing true effects of novel study drugs. In the present
study, we aimed to identify common and uncommon enrollment
criteria from ﬁrst-line DLBCL RCTs in the R-CHOP era and to
develop consensus expert recommendations for modernized
eligibility criteria in the interest of enrolling clinically diverse
study populations that include patients with poor-risk disease
in ﬁrst-line DLBCL RCTs.
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Categorizing eligibility criteria from prior
DLBCL RCTs
We selected DLBCL RCTs representative of ﬁrst-line clinical trials
in the R-CHOP era. We identiﬁed studies that ranged from initial
RCTs investigating R-CHOP in the ﬁrst-line treatment of DLBCL
through recent RCTs examining R-CHOP plus targeted therapy.
We prioritized RCTs for inclusion based on access to study protocols through prior work14 or that were available as published supplemental materials. We selected this timeframe in the interest of
assessing the full range of eligibility criteria in ﬁrst-line clinical trials
during the R-CHOP era and to capture criteria that may have been
included in earlier studies and carried forward into recent trials
despite lack of modern clinical indication. We tabulated inclusion
and exclusion criteria from analyzed studies using study protocols,
study publications, and information available on clinicaltrials.gov and
calculated the average number of enrollment criteria per trial. After
tabulating enrollment criteria, we further categorized enrollment criteria from selected studies into discrete criterion categories (eg, individual eligibility criteria pertaining to creatinine thresholds were
categorized under the criterion category “renal function”). Common
criterion categories were deﬁned as those present in greater than or
equal to two-thirds of RCTs, moderately common criterion categories were present in greater than or equal to one-third and fewer
than two-thirds of RCTs, and uncommon criterion categories were
present in fewer than one-third of RCTs.

Delphi-method survey
We conducted a Delphi-method survey15,16 with a panel of experts
in lymphoma clinical trial design to identify consensus-essential and
consensus-unnecessary eligibility criteria for ﬁrst-line DLBCL RCTs.
Survey participants were asked to complete a Delphi-method questionnaire regarding recommendations for modernized eligibility criteria with the speciﬁed aim of reducing DTI and increasing enrollment
of patients with poorest-risk disease while maintaining patient safety
in ﬁrst-line DLBCL RCTs. Invited survey participants included clinical
investigators and experts in biostatistics involved in the Lymphoma
Epidemiology of Outcomes Cohort Study representing 8 academic
medical centers in the United States. We derived eligibility criteria
for inclusion in the survey based on common and moderately common eligibility criterion categories as tabulated from the prior
DLBCL RCTs in order to focus expert discussion on eligibility criteria that were frequently included in ﬁrst-line DLBCL RCTs in the
R-CHOP era. We omitted criteria from inclusion in the survey that
we believed were necessary for patient safety and would not foster
discussion during the Delphi-method survey. We asked prospective
survey participants to recommend additional pertinent eligibility criteria for inclusion in the survey that were not already represented after
tabulation from analysis of the prior ﬁrst-line DLBCL RCTs. See supplemental Figure 1 for a ﬂowchart illustrating the criterion category
selection process for inclusion in the Delphi-method survey.
The survey consisted of 3 rounds and was conducted via e-mail
using Google Forms. In the ﬁrst round, we asked survey participants
to rate the importance of each eligibility criterion using a 1 to 9
Likert-style scale (1 5 unnecessary for inclusion in future RCTs;
9 5 essential). Survey participants were able to see a list of prospective survey respondents but did not have access to current
responses of other members of the survey group when completing
10 MAY 2022 • VOLUME 6, NUMBER 9
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Diffuse large B-cell lymphoma (DLBCL) is the most common adult
non-Hodgkin lymphoma (NHL) and is clinically heterogeneous.1,2
Although 60% of patients with DLBCL who receive standard ﬁrst-line
treatment with rituximab, cyclophosphamide, doxorubicin, vincristine,
and prednisone (R-CHOP) will experience a cure,3 the remaining
40% exhibit a median overall survival under 1 year, indicating signiﬁcant unmet treatment needs for patients in poorest-risk groups.4
Recent randomized controlled clinical trials (RCTs) designed to
improve ﬁrst-line therapy for DLBCL have shown consistent negative
results5-11 that may be due in part to time-intensive assessment of eligibility status limiting enrollment of patients who require urgent
therapy.12

Methods

In the second round, we invited all round-1 survey participants to
reassess eligibility criteria that were unresolved or in disagreement
after round 1. Round 2 employed the methods used in round 1 and
requested recommendations for threshold values for quantitative criteria. Survey options for quantitative threshold values were selected
from threshold values used in the analyzed DLBCL RCTs from the
R-CHOP era. The second-round survey also included free-text ﬁelds
for survey respondents to provide context for their recommended
threshold values or to suggest other threshold values. Statistical
analyses conducted after round 2 included repeating analyses conducted following the round-1 survey as well as calculating the magnitude of change between round-1 and round-2 Likert ratings by
criterion (ie, round-2 Likert value minus round-1 Likert value) by
respondent for each respondent who participated in both round 1
and round 2. In addition, we calculated the frequency of quantitative
thresholds selected by the expert panel for quantitative eligibility criteria. Based on survey results, we developed preliminary recommendations for eligibility criteria. A ﬁnal survey asked all round-1 survey
participants whether they agreed or disagreed with each preliminary
recommendation and to provide additional context or explanation for
their response. We developed ﬁnalized recommendations for eligibility criteria based on survey results. All authors reviewed our ﬁnalized
recommendations for consensus, modernized eligibility criteria in
ﬁrst-line DLBCL RCTs.

Statistical analysis
We performed statistical analyses using R version 3.6.2 or greater.

Results
Categorizing eligibility criteria from prior
DLBCL RCTs
We selected 19 DLBCL RCTs for analysis that spanned the
R-CHOP era (Table 1). Notably, this study was designed and initiated before the authors had access to eligibility criteria from the
REMoDL-B17 and GOYA18 trials (see “Discussion” and supplemental data for further analysis incorporating these RCTs). Across all
10 MAY 2022 • VOLUME 6, NUMBER 9

trials, we tabulated 451 total enrollment criteria, with an average of
23.7 criteria per study (standard deviation, 6.3; range 14 to 37 criteria). Analysis of the 451 tabulated enrollment criteria revealed 51
discrete criterion categories (Table 2) across the 19 RCTs including
18 common, 11 moderately common, and 22 uncommon criterion
categories.

Delphi-method survey
We derived 30 total eligibility criterion categories for inclusion in the
survey from common and moderately common criterion categories
in the 19 DLBCL RCTs. From 29 common and moderately common
criterion categories, 3 criterion categories were expanded for inclusion in the survey as follows: “histology” was expanded to include
cell-of-origin (COO) subtype and CD20 positivity; “female reproductive concerns” was expanded to include pregnancy status, breastfeeding status, and contraception or abstinence; and “other
neurologic pathology” was expanded to include peripheral neuropathy and history of stroke or intracranial hemorrhage. We omitted 3
criteria that we believed were necessary for patient safety (clinical
contraindications to study therapy, known allergy or hypersensitivity
reaction to study drugs, and whether the patient is receiving or has
received contraindicated therapies that would preclude receiving
study therapy). Prior to initiation of the ﬁrst-round survey, 1 additional eligibility criterion category, “central pathology review prior to
enrollment,” was proposed for inclusion in the questionnaire by a
prospective survey participant for a total of 31 criterion categories
included in the survey.
Among 29 clinical investigators invited to participate in the Delphimethod survey, 17 respondents including physicians and experts in
biostatistics representing 8 academic medical centers in the United
States completed the round-1 survey for a response rate of 58.6%.
The median number of years’ experience in hematology/oncology
among respondents was 17 years (IQR, 12 years; range, 3-30
years). The ﬁrst round examined the previously derived 31 eligibility
criterion categories. After the ﬁrst-round survey, 12 of 31 criteria
(39%) qualiﬁed as essential, 9 (29%) qualiﬁed as unnecessary, 2
(6%) showed disagreement, and 8 (26%) remained unresolved
(Figure 1A). Essential criteria with the highest median Likert-style
values included pregnancy status, breastfeeding status, and whether
the patient was already receiving an investigational drug. Unnecessary criteria with the lowest median rankings included minimum life
expectancy, HCV status, and central pathology review prior to
enrollment. See supplemental data for results of all survey rounds.
Fifteen of 17 ﬁrst-round respondents participated in the second
round (response rate, 88.2%). Participants reassessed 10 criteria
that had shown disagreement or remained unresolved. Based on
round-2 results, 1 additional criterion, performance status, was
deemed essential (Figure 1B). Although study participants commonly changed their Likert-style rankings between rounds 1 and 2
of the survey as illustrated in round-2 survey results available in
supplemental data, the remaining 9 criteria continued to show disagreement or remain unresolved. Survey participants provided recommendations for threshold values for 10 quantitative eligibility
criteria including measurements of renal, hepatic, and cardiac function, threshold levels for platelet count and white blood cell count,
and recommended dimensions for measurable disease on imaging.
Twelve of 17 ﬁrst-round participants responded to the ﬁnal survey
regarding preliminary recommendations (response rate, 70.6%).
IMPROVING ELIGIBILITY CRITERIA FOR DLBCL RCTS
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questionnaires. In addition, the ﬁrst-round survey requested the total
number of years each participant had worked in hematology/oncology. Based on ﬁrst-round results, we designated each eligibility criterion as essential, unnecessary, unresolved, or in disagreement.
Essential criteria had a median Likert value $7. Unnecessary criteria
had a median value #3. Criteria were in disagreement if greater
than one-third of respondents selected a value $7 and greater than
one-third selected a value #3. Unresolved criteria showed median
values from 4 to 6 and were not in disagreement. Statistical analyses related to survey results included median, range, and interquartile range (IQR) values for number of years’ experience in
hematology/oncology; frequency, median, and IQR values for Likert
values by eligibility criterion; and percentage of criterion categories
designated as essential, unnecessary, unresolved, or in disagreement. Respondents received a personalized summary of round-1
results including median values and IQRs for all included criteria,
histograms showing the ranking value distribution for each criterion,
indication of the participant’s personal Likert response by criterion,
and comments from survey participants for each eligibility criterion. All survey responses including Likert rankings and comments
were anonymized in personalized summaries received by survey
participants.

Table 1. Randomized controlled trials included in analysis (n 5 19)
Study identiﬁer

Accrual start year

30-32

n

Treatment

LNH-98.5

1998

399

ECOG 4494/CALGB 979333

1998

546; 342

LNH-98.334

1999

474; 269

RICOVER-6035

2000

1215

2000

796

CHOP-like vs R-CHOP-like

DSHNHL 2002-1

2003

261

R-CHOEP-14 vs R-MegaCHOEP followed by ASCT

ANZINTER339

2003

224

R-CHOP-21 vs R-miniCEOP

LNH03-1B40

2003

223

ACVBP† vs R-ACVBP†

LNH03-2B41

2003

379

R-CHOP-21 vs R-ACVBP†

42

MInT36,37
38

CHOP-21 vs R-CHOP-21
R1: CHOP-21 vs R-CHOP-21; R2: observation vs rituximab
R1: ACE vs ACVBP*; R2: observation vs rituximab
6 cycles CHOP-14 vs 8 cycles CHOP-14 vs 6 cycles R-CHOP-14 vs 8 cycles R-CHOP-14

600

R-CHOP-14 vs R-CHOP-21

2004

681

Observation vs rituximab

PIX20344

2005

122

R-CHOP-21 vs R-CPOP

R-CHOP-14 vs R-CHOP-2145

2005

1062

MAIN

46

R-CHOP-14 vs R-CHOP-21

2007

748

R-CHOP-14 or R-CHOP-21 vs RA-CHOP-14 or RA-CHOP-21

PYRAMID7

2009

206

R-CHOP-21 vs VR-CHOP

ECOG-ACRIN 141247

2013

280

R-CHOP-21 vs R2CHOP

PHOENIX48

2013

844

R-CHOP-21 vs R-CHOP 1 brutinib

ROBUST49

2015

570

R-CHOP-21 vs R-CHOP 1 lenalidomide

50

2017

875

R-CHOP-21 vs R-CHP 1 polatuzumab vedotin

POLARIX

ACE, doxorubicin, cyclophosphamide, and etoposide; ASCT, autologous stem cell transplantation; CHOP-21, cyclophosphamide, doxorubicin, vincristine, and prednisone given every
21 days; DSHNHL, Deutsche Studiengruppe Hochmaligne Non-Hodgkin-Lymphome; ECOG-ACRIN, Eastern Cooperative Oncology Group and the American College of Radiology
Imaging Network; HDT, high-dose therapy; MInT, Mabthera International Trial; R1, ﬁrst randomization; R2, second randomization; R2CHOP, R-CHOP plus lenalidomide; RA-CHOP,
R-CHOP plus bevacizumab; R-ACVBP, ACVBP plus rituximab; R-CHOEP-14, rituximab, cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone given every 14 days;
R-CHOP-21, rituximab 1 CHOP given every 21 days; R-CHP, rituximab, cyclophosphamide, doxorubicin, and prednisone; R-CPOP, rituximab, cyclophosphamide, pixantrone, vincristine,
and prednisone; R-MegaCHOEP, R-CHOEP with dose-escalated cyclophosphamide, etoposide, and doxorubicin; R-miniCEOP, rituximab, cyclophosphamide, epirubicin, vinblastine, and
prednisone; VR-CHOP, R-CHOP plus bortezomib.
*ACVBP, doxorubicin, cyclophosphamide, vincristine, bleomycin, and prednisone.
†ACVBP, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone.

Across all criteria, the average rate of agreement among lymphoma
experts in support of preliminary recommendations was 90.4% (standard deviation, 9.7%). Nine preliminary recommendations showed
100% agreement across survey respondents, and 23 of 31 criteria
had $90% agreement. See supplemental data for data regarding
agreement among experts with preliminary recommendations by criterion. Panel experts established ﬁnal recommendations for all eligibility
criteria assessed in prior survey rounds (Table 3).

Discussion
We reﬁned eligibility criteria for frontline DLBCL RCTs utilizing a
Delphi-method survey that incorporated recommendations from a
multi-institution panel of lymphoma experts from academic medical
centers in the United States. We deﬁned consensus recommendations for 31 eligibility criteria including threshold values for 10 quantitative criteria, and we identiﬁed 13 essential and 9 unnecessary
criteria from criteria common to DLBCL RCTs in the R-CHOP era.
Notably, our survey group liberalized or identiﬁed as unnecessary
multiple criteria that were frequently included in prior DLBCL RCTs,
emphasizing the importance of updating preenrollment assessments
that became commonplace over time but are no longer clinically
indicated in modern RCTs. We believe that our recommendations
for updated threshold values and for eliminating criteria deemed currently unnecessary by the survey group can streamline trial enrollment and shorten DTI. This approach aligns with recommendations
2748
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from national panels of experts for enhancing enrollment in cancer
clinical trials.19-21 Further, survey results address multiple issues we
believe are pertinent to reduce DTI in DLBCL RCTs including eliminating central pathology review prior to enrollment and allowance of
prephase corticosteroids or bridging therapy prior to administering
study drugs. Final recommendations for eligibility criteria showed
strong agreement among survey respondents and are readily applicable in frontline DLBCL trials. It is our hope that the consensus
recommendations included in this study will streamline the enrollment process for ﬁrst-line DLBCL RCTs, shorten DTI for ensuing
study populations, and increase the likelihood of identifying true
effects of novel drugs for ﬁrst-line treatment of DLBCL.
Notably, although survey respondents designated 22 eligibility criteria as essential or unnecessary, 9 criteria remained either unresolved
or showed disagreement, illustrating the challenges inherent in
reaching full consensus among experts in clinical trial design.
Review of survey results shows that essential criteria generally pertained to safety of study drugs (eg, pregnancy and breastfeeding
status), prognostic factors (eg, IPI score, age at diagnosis, and Ann
Arbor stage), and patient-speciﬁc clinical factors including renal and
hepatic function. Regarding IPI score, it should be noted that the
survey group advised inclusion of IPI score or elements of the IPI
score in eligibility criteria at this time given that patients with low IPI
score have favorable outcomes with standard therapies, allowing for
selection of patients in greatest need of trials. However, survey
10 MAY 2022 • VOLUME 6, NUMBER 9
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2003

NHL1343

LNH03-6B

Table 2. Criterion categories in 19 DLBCL RCTs

Number of studies
with criterion category
n (%)

Common criterion
categories (present in
>66% of RTs; n 5 18
categories)

Number of
studies
with criterion
category
n (%)

Moderately common
criterion categories
(present in 33% to 66%
of RCTs; n 5 11
categories)

Number of
studies with
criterion
category
n (%)

Uncommon criterion
categories (present in
<33% of RTCs; n 5 22
categories)

Age (y)

11 (58)

HCV status

6 (32)

Pulmonary function

19 (100)

Histology

11 (58)

Participation in other study

6 (32)

Sex

19 (100)

History of other malignancies

10 (53)

Other neurologic pathology

6 (32)

Recent surgical history

19 (100)

Prior DLBCL treatment

9 (47)

Hypersensitivity to study drugs

5 (26)

Diabetes mellitus

19 (100)

Renal function

9 (47)

Other infectious disease status

5 (26)

Patient compliance

18 (95)

Hepatic function

8 (42)

Imaging

4 (21)

Adult patient under tutelage

18 (95)

HIV status

8 (42)

Minimum life expectancy

4 (21)

Coagulopathy

17 (89)

Cardiac function

7 (37)

Contraindicated therapies

4 (21)

Uncontrolled hypertension

16 (84)

CNS involvement by lymphoma

7 (37)

History of transformed lymphoma

3 (16)

Hemoglobin (g/dL)

16 (84)

Performance status

7 (37)

Male reproductive concerns

3 (16)

History of PTLD

15 (79)

Contraindications to study therapy

7 (37)

Psychiatric history

3 (16)

Organ transplant history

15 (79)

IPI score

2 (11)

Bone marrow inﬁltration

14 (74)

Female reproductive concerns

2 (11)

Gastrointestinal function

14 (74)

HBV status

2 (11)

HTLV-1 status

14 (74)

Other organ dysfunction

1 (5)

CGA score

14 (74)

Platelet count (platelets per mL)

1 (5)

LDH level

14 (74)

WBC count (cells per mL)

1 (5)

Orthopedic history

13 (68)

Ann Arbor stage

1 (5)

Physical exam ﬁndings

1 (5)

Rheumatologic disease

1 (5)

Substance use

1 (5)

Tumor invasion of major blood vessels

1 (5)

Vaccination history

CGA, comprehensive geriatric assessment; CNS, central nervous system; HTLV-1, human T-lymphotropic virus 1; LDH, lactate dehydrogenase; PTLD, posttransplant
lymphoproliferative disorder; WBC, white blood cell.

respondents emphasized that a better understanding of DLBCL
biology may someday allow us to move beyond IPI score as an eligibility criterion. Unnecessary criteria included comorbid disease
states that may warrant evaluation as part of routine clinical practice
but are now clinically manageable during trial participation and
should not preclude eligibility (eg, HIV, HBV, and HCV status). Similarly, preenrollment steps that would slow enrollment and increase
DTI (eg, central pathology review prior to trial participation) were
deemed unnecessary. Regarding eligibility criteria that remained
unresolved or showed disagreement, the survey group commonly
concluded that assessing the importance of these criteria required
additional, case-by-case information. The additional information
required may depend on the purpose of a given study, with the survey group advising, for example, that assessment of COO subtype
should be included as an eligibility criterion only if the study drug
targets COO subtypes. Alternately, the additional needed information may relate to the investigational therapy in question; for example, the survey group recommended that inclusion of platelet count
thresholds should depend on whether the study drug is known to
cause thrombocytopenia. Lastly, the required case-by-case information may pertain to the medical history of the patient being evaluated
for inclusion. For example, the survey group concluded that a
patient’s underlying cardiac function is pertinent in any study that
10 MAY 2022 • VOLUME 6, NUMBER 9

includes an anthracycline, but assessment of left ventricular ejection
fraction for all prospective patients prior to trial participation regardless of clinical indication may unnecessarily increase DTI. Criteria
that remained unresolved or showed disagreement also involved
factors inﬂuencing R-CHOP dose reduction or conditions likely to
be exacerbated by R-CHOP toxicity. There was not investigator consensus regarding whether these criteria should be requirements for
eligibility or applied using clinical judgment as physicians determine
which patients to consider for enrollment. Finalized recommendations for eligibility criteria account for the added nuance of criteria
that were unresolved or showed disagreement and can be readily
applied to modern ﬁrst-line DLBCL RCTs.
Multiple recent studies describe the importance of modernizing eligibility criteria for clinical trials in oncology including analyses
highlighting criteria pertaining to minimum age threshold,21 comorbid organ dysfunction,22 and HIV status.23 In addition, recent examinations focused on DLBCL in particular indicate that organ-function
based eligibility criteria in DLBCL RCTs limit inclusion of patients
with poorest-risk disease24,25 and that DLBCL trial eligibility criteria
have become increasingly restrictive over time, likely limiting recruitment.26 Our work addresses this urgent research gap by updating
and streamlining enrollment criteria with important ramiﬁcations for
inclusion of poor-risk patients in ﬁrst-line DLBCL RCTs. It is our
IMPROVING ELIGIBILITY CRITERIA FOR DLBCL RCTS

2749

Downloaded from http://ashpublications.org/bloodadvances/article-pdf/6/9/2745/1894246/advancesadv2021006504.pdf by guest on 27 May 2022

19 (100)

A
Pregnancy status
Breastfeeding status
Participation in other study or treatment
with other investigational drug
Female: contraception or abstinence
CNS involvement
Stage
Male: contraception or abstinence
Renal function
Presence of other significant, uncontrolled,
concomitant disease at investigator’s discretion
Hepatic function
IPI
Prior DLBCL treatment
Performance status
Cardiac function
Measurable disease on imaging
Platelet count
WBC
Active infection requiring systemic therapy
History of transformed lymphoma
COO subtype
Peripheral neuropathy
Survey outcome

HIV status

Consensus
essential
(median, IQR)

History of stroke or intracranial hemorrhage
History of other malignancies
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Figure 1. Results from a Delphi-method survey conducted with lymphoma trial experts to modernize enrollment criteria for ﬁrst-line DLBCL RCTs
comparing R-CHOP vs R-CHOP plus targeted therapy. Round 1 (A) included 31 total criterion categories common to ﬁrst-line DLBCL RCTs spanning the R-CHOP
era. Criteria with median Likert-style values $7 were deemed essential. Criteria with median values #3 were deemed unnecessary. Criteria with median values .3 and ,7
were either unresolved or showed disagreement based on response distribution and were revisited in round 2 (B). CD20, cluster of differentiation 20; CNS, central nervous
system; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeﬁciency virus; IPI, international prognostic index; WBC, white blood cell.
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Age

Table 3. Consensus recommendations for eligibility criteria in ﬁrst-line DLBCL RCTs based on a Delphi-method survey of lymphoma
clinical trials experts
Criterion

Recommendation

Essential criteria
Pregnancy status

Pregnant women should be excluded from enrollment.

Breastfeeding status

Breastfeeding should be prohibited during trial participation.
Effective contraception or abstinence from heterosexual intercourse is required for enrollment if of childbearing potential.

Male: contraception or abstinence

Effective contraception or abstinence from heterosexual intercourse is required for enrollment.

Participation in other study or treatment
with other investigational drug

Study participants should receive no concurrent treatment with any other investigational therapy. Study participants should
have received no treatment within the last 30 d with any other investigational therapy. Participation in nontherapeutic
studies (eg, subject registries) is permitted.

IPI score

We recommend inclusion of IPI score as an eligibility criterion. No single IPI score range is recommended. IPI score range
should be determined based on the target population for a given study. Alternately, consider using discrete elements of IPI
as eligibility criteria rather than total IPI value.

Ann Arbor stage

Patients with Ann Arbor stages II-IV should be eligible for enrollment. Inclusion of patients with stage-I disease should depend
on the study hypothesis and should be determined on a trial-by-trial basis.

Age at diagnosis

At baseline, patients aged $ 18 y should be eligible for trial participation. Determine ﬁnal age range based on study
intervention and target population, though most ﬁrst-line RCTs do not require additional age cutoffs beyond age $ 18 y.

Performance status

We recommend including patients with PS of ECOG 0-2 and ECOG 3 if poor PS is due to lymphoma.

Renal function

Exclude patients based on a selected threshold value for renal function unless renal dysfunction is attributable to lymphoma.
Selection of threshold value should take into account speciﬁc therapies in trial. Allow for use of both a Cr threshold and a
CrCl threshold from the following ranges:
 Eligible if Cr #1.5-2.0 mg/dL
 Eligible if Cr #1.5-2.0 3 ULN
 Eligible if CrCl $30 mL/min
Consider more conservative threshold values if investigational drug has known nephrotoxicity. Consider more liberal threshold
values for older participants.

Hepatic function

Exclude patients based on selected threshold values for hepatic function unless hepatic dysfunction is attributable to
lymphoma or Gilbert’s syndrome. Selection of threshold values should take into account speciﬁc therapies in trial. Select
baseline eligibility thresholds from the following ranges:
 Eligible if total bilirubin #1.5-23 ULN
 Eligible if total bilirubin #2-3 mg/dL
 Eligible if transaminases #2.5-53 ULN
Consider more conservative threshold values for hepatic function if investigational drug has known hepatotoxicity.

CNS involvement

No known CNS involvement by lymphoma should be permitted in frontline trials evaluating strategies to improve standard of
care therapy.
Testing for CNS lymphoma is not required for enrollment and should be performed only when based on clinical suspicion.

Presence of other signiﬁcant, uncontrolled,
concomitant disease at investigator’s discretion

No other signiﬁcant, uncontrolled, concomitant disease should be permitted at investigator’s discretion.

Unnecessary criteria
CD20 positivity

Assessment of CD20 positivity is standard for diagnosis but should not be included as an eligibility criterion for enrollment in
ﬁrst-line clinical trials unless the investigational drug requires CD20 positivity to be efﬁcacious.

Central pathology review prior to enrollment

Do not include central pathology review prior to enrollment as an eligibility criterion.

History of other malignancies

Do not enroll patients with another currently active malignancy at investigator's discretion, other malignancy requiring treatment
that would preclude administration of study drugs, or other malignancy likely to be fatal during the trial evaluation window.
Otherwise, do not include history of other malignancies as an eligibility criterion.

History of stroke or intracranial hemorrhage

If the experimental drug is known to increase risk for future CVA, do not include patients with a history of stroke or intracranial
hemorrhage in the past 6 mo.

Psychiatric illness

Do not include psychiatric illness as an eligibility criterion. Inability to comply with study protocols, demonstrate decisionmaking capacity, or participate in informed consent (unless a legally authorized representative provides consent on the
patient's behalf) should preclude study enrollment, regardless of the underlying reason.

HIV status

Although HIV testing should be performed as part of standard clinical practice, HIV infection should not preclude trial
enrollment. Patients with HIV who have adequate viral suppression and disease control should be evaluated and monitored
for potential drug-drug interactions with experimental therapies but otherwise should be considered eligible for trial
participation.

HBV status

Although HBV testing should be performed as part of standard clinical practice, HBV infection should not preclude trial
enrollment. Patients with HBV who have adequate viral suppression and disease control should be evaluated and
monitored for potential drug-drug interactions with experimental therapies but otherwise should be considered eligible for
trial participation.

ANC, absolute neutrophil count; CD20, cluster of differentiation 20; CNS, central nervous system; Cr, creatinine; CrCl, creatinine clearance; CVA, cerebrovascular accident;
EF, ejection fraction; PS, performance status; R-CHOP 1 X, R-CHOP plus targeted therapy; ULN, upper limit of normal.
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Female: contraception or abstinence

Table 3. (continued)
Criterion

Recommendation

HCV status

Although HCV testing should be performed as part of standard clinical practice, HCV infection should not preclude trial
enrollment. Patients with HCV who have adequate viral suppression and disease control should be evaluated and
monitored for potential drug-drug interactions with experimental therapies but otherwise should be considered eligible for
trial participation.

Minimum life expectancy

Do not include minimum life expectancy as an eligibility criterion.

Unresolved criteria
Generally speaking, no prior DLBCL treatment should be permitted for enrollment except treatment with corticosteroids or 1
cycle of chemotherapy at investigator’s discretion. This criterion should be tailored to the hypothesis and target population
in a given study.

Cardiac function

Determine whether to include assessment of cardiac function as an eligibility criterion based on the toxicity proﬁle of study
drugs.
If the study includes an anthracycline, include assessment of cardiac function as an eligibility criterion using the following
criteria:





No cardiac contraindication to an anthracycline
No non-compensated heart failure
No active heart disease in the past six months at the investigator's discretion
EF $ 45%

Platelet count

Patients with platelet count $75 000 platelets/mL are eligible for enrollment unless levels are attributable to bone marrow
inﬁltration or spleen involvement by DLBCL. If the study drug is known to cause thrombocytopenia, consider a higher
threshold value. If low platelets are due to lymphoma, patients with platelet count $50 000 platelets/mL are eligible for
enrollment. If the study drug is known to cause thrombocytopenia, consider a higher threshold value. Alternately, if low
platelets are due to lymphoma, it may be reasonable to consider no threshold value for enrollment.

Active infection requiring systemic therapy

Patients with a serious, active infection at investigator's discretion should not be permitted to enroll. If a patient with an active
infection is enrolled, resolution of infection at investigator’s discretion is required prior to initiation of study therapy.

History of transformed lymphoma

Patients with a history of treated, indolent lymphoma should not be eligible for enrollment. Patients with untreated, indolent
lymphoma under observation should be eligible for enrollment. Composite lymphoma does not preclude enrollment.

Cell-of-origin subtype

Include COO subtype as an eligibility criterion only if the study is designed to target a COO subtype using the investigational
drug in question. Otherwise, do not include COO subtype as an eligibility criterion.

Peripheral neuropathy

If the experimental drug is known to cause peripheral neuropathy, then exclude patients with neuropathy using a severity
threshold based on the experimental drug’s known toxicity proﬁle. Otherwise, exclude only patients with severe neuropathy,
and include instructions for vincristine dose adjustment for patients with mild and moderate underlying peripheral
neuropathy.

Criteria showing disagreement
Measurable disease on imaging

If the primary endpoint in the trial is treatment response, then patients with measurable disease on imaging $1.5 cm in $1
diameter should be eligible for enrollment. Otherwise, do not include measurable disease on imaging as an eligibility
criterion. Any evidence of disease is sufﬁcient for enrollment.

White blood cell count

Patients with ANC $1000 cells/mL should be eligible for enrollment. Exclude patients with ANC ,1000 cells/mL unless low
levels are attributable to bone marrow inﬁltration or spleen involvement by DLBCL. If low ANC is due to lymphoma, do not
use a threshold value for enrollment.

ANC, absolute neutrophil count; CD20, cluster of differentiation 20; CNS, central nervous system; Cr, creatinine; CrCl, creatinine clearance; CVA, cerebrovascular accident;
EF, ejection fraction; PS, performance status; R-CHOP 1 X, R-CHOP plus targeted therapy; ULN, upper limit of normal.

hope that by focusing on ﬁrst-line DLBCL RCTs, our study will build
on these prior analyses to streamline enrollment speciﬁc to ﬁrst-line
DLBCL clinical trials.
Limitations of our study include a round-1 response rate of 58.6%
with 17 out of 29 invited experts responding to the initial questionnaire. A systematic review of Delphi-method studies showed that
the median number of individuals invited to participate across 80
analyzed Delphi-method studies was 17 prospective participants,15
indicating that the total number of respondents in our survey was
greater than the median number of respondents for studies of this
kind. Nonetheless, the round-1 response rate and sample size may
limit generalizability of study results. Response rates for subsequent
rounds of the survey showed sustained participation among panel
experts, with 88.2% and 70.6% of e-mailed survey participants
replying to the round-2 and preliminary-recommendations questionnaires, respectively. Additionally, it should be noted that invited
respondents in the present study were limited to physicians and
experts in biostatistics representing major academic medical centers
2752

HARKINS et al

in the United States. The selection of experts for the survey panel
has an important impact on survey results, and a similar study conducted with different stakeholders (eg, representatives of community
health centers, ethics committees, or pharmaceutical companies) or
conducted in a different region (eg, outside the catchment area of
major academic medical centers or outside the United States) may
reach different consensus recommendations for eligibility criteria in
ﬁrst-line DLBCL RCTs. However, our survey respondents represent
a diverse group of lymphoma clinical trials research experts with
considerable depth and breadth of clinical research experience,
which achieves a key objective for enhancing enrollment in clinical
trials for diverse populations based on prior recommendations.19,27
The scope of the present study was limited to identifying consensus
recommendations for eligibility criteria from expert clinical investigators in the United States, and survey results may not be representative of opinions, perspectives, or local issues relevant to trial design
in other areas. Recommendations from additional stakeholders could
enrich the discussion regarding modern eligibility criteria in ﬁrst-line
DLBCL RCTs.
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Prior DLBCL treatment

We believe that the recommended eligibility criteria included in this
study are ready for application to novel ﬁrst-line DLBCL RCTs.
S1918 (NCT 04799275), a phase 2/3 RCT focused on treatment
of newly diagnosed DLBCL and other lymphomas in patients ages
75 or older, is currently recruiting patients and adheres to many recommendations included in the present study, illustrating the potential of ﬁnalized recommendations to help guide development of
future DLBCL clinical trials. Next steps for this work beyond direct
application in modern DLBCL RCTs include combining recommended eligibility criteria with large DLBCL patient data sets to analyze demographic and outcomes data of prospective patient cohorts
deﬁned using proposed criteria. A recent study examining the
10 MAY 2022 • VOLUME 6, NUMBER 9

impact of trial eligibility criteria on outcomes in a nationwide cohort
of patients with newly diagnosed DLBCL suggests that real-world
data can be used to evaluate the impact of eligibility criteria on prospective ﬁrst-line DLBCL study populations.25 This would enable
modiﬁcation of recommended criteria as needed prior to development of future studies and could further increase the likelihood of
enrolling a more clinically diverse patient population that includes
poor-risk groups. Additionally, application of recommended eligibility
criteria to DLBCL data sets that incorporate patient-level genetic
characteristics would allow for anticipation of ensuing genetic
cohorts when using ﬁnalized eligibility criteria and would facilitate
development of future clinical trials incorporating novel targeted therapies. Although we believe that modernizing eligibility criteria is an
important step toward increasing enrollment of poor-risk groups,
additional research is needed in other avenues that may address
DTI and barriers to trial participation including efforts to increase
access, engagement of community sites, timely drug delivery,
streamlined molecular testing when applicable, selection of time
windows for meeting screening eligibility criteria, baseline imaging
modalities, and other factors beyond the scope of the present
study.
Applying modernized eligibility criteria has important implications for
reducing the number and nature of preenrollment evaluations for all
patients, enabling participation of patients who require urgent therapy in particular, and increasing generalizability of study results for
ﬁrst-line DLBCL RCTs. Given the identiﬁed impact of DTI on enrollment of poor-risk patients in ﬁrst-line DLBCL trials,11 it is our hope
that application of our expert consensus recommendations for eligibility criteria in ﬁrst-line DLBCL RCTs will facilitate enrollment of a
more clinically diverse patient population and increase generalizability of study results while maintaining patient safety.
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Strengths of the present study include the incorporation of expert
opinion from clinical investigators with signiﬁcant experience in ﬁrstline DLBCL RCTs to deﬁne streamlined essential and unnecessary
eligibility criteria. The expert panel included senior clinical investigators; Lymphoma Committee chairs from SWOG, ECOG-ACRIN,
and the Alliance; and members and chairs from the National Cancer
Institute Lymphoma Steering Committee. Additionally, survey results
exhibited high agreement rates for recommendations among lymphoma experts across proposed eligibility criteria (see supplemental
data for concordance rates for preliminary criteria prior to development of ﬁnalized recommendations). Lastly, incorporation of inclusion and exclusion criteria from 19 DLBCL clinical trials from the
R-CHOP era places our methods in context with pivotal trials spanning the relevant history of DLBCL RCTs. We considered whether
these methods overemphasized eligibility criteria that were included
early in the R-CHOP era but were excluded from more recent studies. When restricting analyzed trials to recent DLBCL RCTs that
examined targeted therapies and included R-CHOP in the control
arm, categorization of common and moderately common criteria
yielded largely similar results when compared with criterion categories incorporating all 19 analyzed studies (supplemental Table 1).
We also considered whether inclusion of additional ﬁrst-line DLBCL
RCTs from the R-CHOP era would have altered our results and
yielded different survey questions in the Delphi-method survey. We
examined inclusion and exclusion criteria from 2 DLBCL RCTs not
included in analysis, REMoDL-B17 and GOYA,18 and reassessed
common, moderately common, and uncommon eligibility criterion
categories with the addition of these RCTs (supplemental Table 2).
Eligibility criteria from both studies showed considerable overlap
with common criteria from the previously analyzed 19 DLBCL
RCTs, indicating that our survey was representative of eligibility criteria from ﬁrst-line DLBCL RCTs in the R-CHOP era. With the
REMoDL-B and GOYA studies included, 2 criterion categories, pulmonary function and recent surgical history, changed from uncommon to moderately common criterion categories and thereby would
have been included in the Delphi-method survey if these additional
studies had been incorporated in analysis. All other common and
moderately common criterion categories remained the same with
inclusion of the REMoDL-B and GOYA studies, yielding no further
changes to the Delphi-method survey. It should be noted that the
majority of RCTs included in analysis that incorporated assessment
of pulmonary function in enrollment criteria stipulated exclusion
based on substantial pulmonary impairment or uncontrolled chronic
obstructive pulmonary disease, which were arguably captured in our
Delphi-method survey under the criterion category “presence of
other signiﬁcant, uncontrolled, concomitant disease at investigator’s
discretion.”
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